Celcuity Q4/FY2022 net loss $11.6M/$40.4M; cash runway extended through 2025 after $100M PIPE

Celcuity Inc.

Net loss Q4 2022 $11.6M ($0.69/sh); full year net loss $40.4M ($2.64/sh).
Dosed first patient in Phase 3 VIKTORIA-1 trial, triggering $100M PIPE closing and $20M term loan drawdown.
Cash runway expected through 2025; combined with debt facility and existing cash.
Updated Phase 1b data at SABCS: median PFS 42.3 months in treatment-naive advanced breast cancer.
Enrollment ongoing in FACT-1/2 for CELsignia; interim results expected H2 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported the fiscal year ended December 31, 2022 results: net income $40.4 million, EPS $2.64 loss per share.

Period: the fiscal year ended December 31, 2022
Net income: $40.4 million
EPS: $2.64 loss per share
Result: reported results

Exact text from the filing

Net loss for the full year 2022 was $40.4 million, or $2.64 loss per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported the fourth quarter ended December 31, 2022 results: net income $11.6 million, EPS $0.69 loss per share.

Period: the fourth quarter ended December 31, 2022
Net income: $11.6 million
EPS: $0.69 loss per share
Result: reported results

Exact text from the filing

Net loss for the fourth quarter of 2022 was $11.6 million, or $0.69 loss per share

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-008693

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.